Skip to content
    Real-World Studies

    ALBI score changes predict survival in advanced HCC, cohort study shows

    Duc et alJournal of Liver Cancer

    ALBI score changes predict survival in advanced HCC, cohort study shows
    In patients with unresectable advanced hepatocellular carcinoma (HCC) receiving first-line tyrosine kinase inhibitor (TKI) therapy with sorafenib or lenvatinib, longitudinal assessment of liver function via the albumin-bilirubin (ALBI) score provides critical prognostic insight. In a retrospective cohort study of 73 patients treated between 2022 and 2025 at Ho Chi Minh City Oncology Hospital in Vietnam, monthly monitoring of ALBI scores demonstrated significant progressive hepatic deterioration over a 6-month follow-up period (p < 0.05).
    Hepatic decline occurred irrespective of oncologic response. Patients with progressive disease demonstrated an ALBI increase from -2.64 to -2.02 (p < 0.0001), while those with stable disease also experienced meaningful deterioration, with ALBI rising from -2.77 to -2.46 (p = 0.003), reflecting the combined burden of underlying tumor biology and treatment-related toxicity.
    Overall median overall survival (OS) was 13 months across the cohort, but stratified sharply by baseline ALBI grade: 16 months for grade 1, 10 months for grade 2a, and 8 months for grade 2b (p = 0.042). In addition to baseline grading, the delta ALBI (ΔALBI) at month 3 independently predicted OS (p = 0.032). In the sorafenib subgroup, baseline ALBI was also significantly prognostic for progression-free survival (p = 0.032). Furthermore, higher baseline ALBI grades correlated with treatment intolerance, as grade ≥3 toxicities were significantly more frequent in patients with ALBI grade 2b (p = 0.012).

    Key Takeaways

    • Baseline ALBI grade significantly stratified median overall survival (16 months for grade 1, 10 months for grade 2a, and 8 months for grade 2b; p = 0.042), with 3-month dynamic score change (ΔALBI) serving as an independent prognostic factor for overall survival (p = 0.032).
    • Liver function deteriorated significantly over 6 months regardless of tumor control, worsening in patients with progressive disease (ALBI -2.64 to -2.02; p < 0.0001) as well as those maintaining stable disease (-2.77 to -2.46; p = 0.003).
    • Grade ≥3 adverse events occurred significantly more often with poorer baseline liver function, peaking in the ALBI grade 2b subgroup (p = 0.012).
    Read the original sourceJournal of Liver Cancer